CN107936003A - A kind of compound containing pyridine and thiophene-structure, preparation method and its usage - Google Patents
A kind of compound containing pyridine and thiophene-structure, preparation method and its usage Download PDFInfo
- Publication number
- CN107936003A CN107936003A CN201711495907.XA CN201711495907A CN107936003A CN 107936003 A CN107936003 A CN 107936003A CN 201711495907 A CN201711495907 A CN 201711495907A CN 107936003 A CN107936003 A CN 107936003A
- Authority
- CN
- China
- Prior art keywords
- compound
- rock
- disease
- thiophene
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 74
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims abstract description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 210000002345 respiratory system Anatomy 0.000 claims description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 5
- 229910000489 osmium tetroxide Inorganic materials 0.000 claims description 5
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims description 4
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical class CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical class NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000011435 rock Substances 0.000 description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 238000000605 extraction Methods 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000001035 drying Methods 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000002875 fluorescence polarization Methods 0.000 description 6
- 201000001881 impotence Diseases 0.000 description 6
- 238000007634 remodeling Methods 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 4
- 229960002435 fasudil Drugs 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical class CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical class C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061876 Obstruction Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 235000011167 hydrochloric acid Nutrition 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000000568 rho-Associated Kinases Human genes 0.000 description 3
- 108010041788 rho-Associated Kinases Proteins 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000016160 smooth muscle contraction Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003613 toluenes Chemical class 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- 101150111584 RHOA gene Proteins 0.000 description 2
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 208000030303 breathing problems Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000003029 clitoris Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000011506 response to oxidative stress Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000036259 sexual stimuli Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000003639 vasoconstrictive effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 108091006515 Anion channels Proteins 0.000 description 1
- 102000037829 Anion channels Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- YQPITVOWOGJKBX-UHFFFAOYSA-O CC(C[NH2+]C(C(S)=C(C)C=C(C)C1N(C)C(C)=CC(C)=C1)=O)CO Chemical compound CC(C[NH2+]C(C(S)=C(C)C=C(C)C1N(C)C(C)=CC(C)=C1)=O)CO YQPITVOWOGJKBX-UHFFFAOYSA-O 0.000 description 1
- 0 C[*+]C1=NC(C)=C=CC(C)=C1 Chemical compound C[*+]C1=NC(C)=C=CC(C)=C1 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009306 Clitoral engorgement Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 description 1
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 210000005225 erectile tissue Anatomy 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- -1 triisopropyl borate ester Chemical class 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical technology field, and specifically, the present invention relates to compound of the one kind containing pyridine and thiophene-structure, its preparation method and the application in treatment respiratory disease etc. is prepared.
Description
Technical field
The present invention relates to pharmaceutical technology field, in particular it relates to a kind of containing pyridine and alcoxyl thiophene-structure
Compound, preparation method and its usage.
Background technology
Serine/threonine protein kitase ROCK is made of in human body two kinds of hypotype ROCK I and ROCK II.ROCK I
It is encoded in No. 18 chromosomes, and ROCK II (also referred to as Rho kinases) are then located at No. 12 chromosomes.Both molecular masses
It is each about 160kD.Both (amino acid sequences) have 65% homology, and the homology in wherein kinases area is up to 95%.To the greatest extent
It is much like to manage their sequence, but Tissue distribution is had nothing in common with each other.The expression of ROCK I highest levels can be from heart, lung and bone
Structure observation arrives, and ROCK II are then mainly expressed in brain.Nearest data show that both isomers have the function of part rich
Yu Xing, ROCK I are more related in immunocompetence, and ROCK II are then related in smooth muscle function.
ROCK activity has been demonstrated to be influenced by the one member-GTPaseRhoA of Rho (Ras homologues) gtp binding protein
And strengthen.The RhoA of active form GTP reference states positioned at from the ROCK Rho protein binding domains (RBD) for suppressing carboxyl terminal ring with producing
Raw interaction.After bonding, the interaction between ROCK negativity regulatory region and kinases area is destroyed.This process to swash
Enzyme obtains the opening conformation for being completely in activated state.The opening conformation also by lipid activity factor (such as arachidonic acid) with
The PH domains of kinases carboxy-terminal domains with reference to caused by.Another activation mechanism in apoptosis process is also illustrated,
And it is related to the carboxyl carried out respectively to ROCK I and II through Caspase (caspase) -3 and -2 (or granzyme granzyme B)
End check solution.
ROCK plays an important role in various cell functions, such as smooth muscle contraction, the group of actin cytoskeleton
Knit, platelet activation, the downward of myosin phosphatase cell adherence, the migration of aortic smooth muscle cell, hyperplasia, survival and
Thrombin induction reaction, cardiac myocyte hypertrophy, bronchial smooth muscle contraction, smooth muscle contraction and the restructuring of nonmuscle cells skeleton,
Capacity regulates and controls activation, neural process retraction, wound healing, cell transformation and the gene expression of anion channel.ROCK is also being related to
Play a role in many signal pathways of autoimmunity and aspect of inflammation.ROCK has been demonstrated to play in terms of the activation of NF- κ B
Effect, the NF- κ B are a kind of key molecules for causing Tumor necrosis factor TNF and the generation of other inflammatory cytokines.It was reported that
ROCK inhibitor, which can resist lipopolysaccharides (LPS), stimulates the generation of TNF-α and the IL-6 factors in THP-1 macrophages.Therefore, ROCK
Inhibitor provides beneficial therapy to treat autoimmune disease, diseases associated with inflammation and response to oxidative stress.
Generally speaking, ROCK is the major control point of smooth muscle cell function, and is the inflammation mistake of various inflammatory cells
The crucial signaling component of the fibrosis and remodeling process of journey and many affected organs.There is obvious sign to show that ROCK relate to
The pathogenesis of many diseases, includes asthma, chronic obstructive pulmonary disease and glaucoma in the middle.In addition, ROCK involve it is various
Disease and obstacle, include eye illness, breathing problem, angiocardiopathy and vascular diseases, diseases associated with inflammation, nervous system in the middle
With central nervous system disease, proliferative disease, kidney trouble, sex dysfunction, disease in the blood system, skeletal diseases, glycosuria
Disease, benign prostate hyperplasia, graft-rejection, liver diseases, systemic loupus erythematosus, spasm, hypertension, chronic obstruction
Property bladder disease, premature labor, infection, allergy, obesity, pancreatic disease and AIDS.
With gene knockout model and substantial amounts of academic research illustratively, ROCK looks like the target spot of a safety.This
The data of a little knock out mice and the post-market surveillance research of Fasudil (Fasudil) (go out for treating cavum subarachnoidale
The strong ROCK inhibitor of appropriateness of cerebral angiospasm after blood) combine, it is a real and significant medicine target to indicate ROCK
Mark.ROCK inhibitor can be used as the curative drug that treatment is related to the obstacle of ROCK approach.Therefore, we extremely need exploitation one
Kind can be used for treating the relevant ROCK inhibitor of various and ROCK activation, be especially considering that most of these current diseases are all controlled
Treat deficiency.Some unrestricted examples are glaucoma, asthma and chronic obstructive pulmonary disease.
Glaucoma, one kind may result in the disease of hypopsia and blindness because of optic nerve injury, be because of intraocular pressure
Caused by increase.This is the common cause of adult's blindness, is a kind of chronic disease for needing to control all the life after making a definite diagnosis mostly.
Due to current treatment can only control and can not radical curing of disease, and further by stimulate, side effect locally and systemically, the disease
Disease needs the cure of an improvement.In addition, other positive influences, that is, the anti-inflammatory of ROCK inhibitor and nerve regneration into
Dividing to be prioritized.The ROCK inhibitor of reference such as Y-27632 can change cellular morphology and the TM mankind of reduction incubation are thin
Tonofibrils, Focal adhesions and the MLC phosphorylations of born of the same parents；The human trabecular meshwork shape tissue of their diastole in vitro cultures, diastole are external
Mankind's Schlemm pipeline endothelial cells, can dramatically increase girder outflow when being applied topically to animal, cause advantageously to drop
Low intraocular pressure.
Allergic asthma is a kind of to be immunized instead because heredity susceptible person produces non-habitual to ubiquitous environment albumen
Should, so that the respiratory tract chronic inflammatory diseases triggered.Although there is the treatment method of successful, illness rate because these therapies without
Method is effected a radical cure and increased；Present situation is still being aggravated, and has more and more nonresponders.It can do with all factors of the disease
New, efficient, steroid-sparing be required.
Chronic obstructive pulmonary disease (Chronic Obstructive Pulmonary Disease, COPD) is one group with slow
Property irreversibility respiratory tract is restricted, is characterized with abnormal inflammatory reaction, the remodeling and infringement of bronchoconstriction and lung tissue
Disease.One of the main reason for it is human death, illness rate just steadily increase.Since current therapy is not enough to cure disease
Disease, we seek new treatment method at urgent need.Due to glucocorticoid only have the function that it is limited or absolutely void, because
Bronchodilator is used only in this till now.Quote the separated people's branch gas of ROCK inhibitor energy diastole of such as Y-27632
Pipe prepared product, suppresses the resistance of respiratory tract increase of anesthetized animal, strengthens the diastole effect of the beta-receptor activator of in vitro and in vivo,
And rapid bronchiectasis is given after inhalation.In addition, ROCK inhibitor can block H2O2The tracheal smooth muscle of induction is shunk
(clinical marker of response to oxidative stress).
Relevant with respiratory inflammation to be, ROCK inhibitor can resist the increasing across endothelial cell permeability of antiphlogistic mediation
By force, the barrier integrity of blood vessel endothelium is kept, suppresses the inflow of the eosinophil after internal ovalbumin excites, prevent lung
The formation of oedema and neutrophil migration, suppress anti-to the allergy of methacholine and serotonin in allergy Respiratory Tract of Mice
Tumor necrosis factor (TNF) release of LPS inductions and should be blocked.In terms of respiratory tract fibrosis and remodeling, ROCK inhibitor
The migration that asm cell can be blocked to induce.ROCK is found in the mankind's for the external evidence that Airway Remodeling acts on
Lung cancer cell line, the airway smooth muscle cells of calf and human airway smooth muscle.Internal cards of the ROCK for Fibrosis parameters
According to generally resulting from mouse (myocardial fibrosis that wherein excalation of ROCK causes decay).Y-27632 obstructs for cardiac muscle
The myocardial fibrosis decay of plug and Fasudil (fasudil) for the congestive heart failure of chronic hypertension rat model
Other indication is brought for the importance of remodeling for ROCK.Finally, the apoptosis of ROCK inhibitor increase smooth muscle cell is thin
Born of the same parents lose.
The human sexual response of masculinity and femininity can be produced because of the interaction of physiology, psychology and Hormone Factors.Male and
One of them of female body reaction is common that blood vessel function response, it can be loose because of the vascular smooth muscle that sexual stimulus is brought
Relax, so as to make phallic property tissue congested.Therefore, when the smooth muscle of perineum blood vessel loosens, the blood pressure in penis and clitoris
It is consequently increased with blood flow.The inflow of arterial blood will cause penis or corpora cavernosa clitoridis to expand, so as to cause to erect.Impotence
(male erectile dysfunction) is generally defined as being unable to reach and maintains to carry out the erectile ability for being satisfied with sex expression and sexual intercourse enough.
Impotence be probably because mental handicape, nervous system abnormality or other include the physiological barrier of anhormonia, or many reasons
With reference to causing to form.In the U.S., impotence estimation influences 40% 40 years old male, will be improved by 50 years old with age
To about 50%, by 70 years old when will be up to 67%.Women can also face sex dysfunction with the increase at age, and with climacteric
Breaking-out and the risk of increase vascular diseases.Therefore, as male, the sexual arousal of women is at least part of can be with making clitoris
Congested blood flow increase.The blood flow of vagina also increases the degree of lubrication of vagina.Therefore, Female sexual dysfunction is probably
Caused by being unable to reach or maintaining clitoral engorgement and/or vaginal lubrication in whole sexuality period.At present, it is most of to use
The signal transduction pathway for reducing calcium ion can be targeted in the vasodilator for the treatment of erectile dysfunction, this needs startup blood vessel to put down
The contraction movement of sliding flesh.However, from the point of view of physiological angle, vasoconstrictive startup is a very acute activity, when continuing
Between only from the several seconds to several minutes.Erectile tissue is maintained at by the long-term vessel retraction of calcium dependent/non-dependent signal transduction pathway
Relaxed state.It is RhoA/Rho kinase pathways to keep the vasoconstrictive signal pathway of calcium dependent/non-dependent.ROCK inhibitor is for controlling
It is also corresponding useful to treat erectile dysfunction.Therefore, from the point of view of on the one hand, the present invention is used to treat male or female comprising a kind of
The method of dysfunction, it, which includes including to individuals in need local application, to weaken in organ subject to sexual stimulus
The compound of Rho kinase activities and the composition of pharmaceutically acceptable carrier.
There are several known ROCK inhibitor types at present.Current emphasis is the application of tumour and angiocardiopathy.Arrive
Untill now, the outstanding treatment potentiality of ROCK inhibitor is only limited in limited scope.Its reason is that ROCK is such a
Effectively with extensive biochemical regulator, the systemic inhibitory action of ROCK can bring powerful biological effect, but be also regarded as
The side effect of most of disease treatments.In fact, ROCK inhibitor is subject to the medical application of stronger anti-inflammatory component treatment disease
ROCK key effects adjust smooth muscle cell contraction nourish the stage when obstruction.The ROCK inhibitor of systemic applications can lure
Hair blood pressure is decreased obviously.Therefore, we have ROCK inhibitor of different nature high demand.
In order to specifically be treated by the specific aim for adjusting smooth muscle function and/or inflammatory process and/or remodeling expansion disease,
We can target target organ at high expectations ROCK inhibitor, enter other organs to avoid the medicine of big deal.Therefore, it is local
Or local medicinal application is desired.Under normal conditions, the medicine of topical application is used to treat respiratory tract, eyes, property work(
Can obstacle and dermatopathy.
To sum up, we still have lasting necessary design and exploitation ROCK inhibitor at present, it is wide for therapeutic domain
General morbid state.Compound described herein and pharmaceutically acceptable composition can be used for treatment or mitigate to activate with ROCK
The seriousness of relevant various obstruction and illnesses.More specifically, compound of the invention is preferred for preventing and/or treats extremely
A kind of few disease or obstacle for being related to ROCK, for example, with the function of smooth muscle cell, inflammation, fibrosis, excessive cell Proliferation,
The disease that angiogenesis is excessive, high response, barrier dysfunction, nerve degeneration lesion and remodeling are related.For example, the present invention
Compound can be used for preventing and/or treating following disease and illness：Ophthalmology disease or illness, breathing problem, throat, nose and
It is disease, skin disease, intestines problem, cardiovascular and the vascular diseases of ear, diseases associated with inflammation, the nervous system disease, Hypertrophic
Disease, kidney trouble, sex dysfunction, etc..
The invention discloses ROCK inhibitor of the one kind containing pyridine and alcoxyl thiophene-structure, these compounds can be used for preparing
The medicine of sex dysfunction, diseases associated with inflammation, ophthalmology disease and respiratory disease etc..
The content of the invention
It is an object of the present invention to provide a kind of ROCK inhibitor with general formula I.Another object of the present invention is
There is provided and prepare the method with compounds of formula I.It is also another object of the present invention to provide make containing compounds of formula I
Treat the application of respiratory disease etc..Present invention is specifically described in conjunction with the purpose of the present invention.
Compound of the present invention with logical formula (I) is with following structural formula：
Wherein, X is selected from F, Cl substituent.
Logical formula (I) compound of the present invention can be synthesized by following route：
Thiophene carboxylic acid's compound II is condensed with allylamine III in the presence of DCC, generation thiophene-carboxamides IV；Pyridine bromide V exists
Handled in the presence of triisopropyl borate ester using n-BuLi, obtain compound VI；Compound IV is anti-in Suzuki with compound VI
Reacted under the conditions of answering, coupling obtains compound VII；Compound VII uses OsO4With N-methylmorpholine N- oxides (NMMO) place
Reason, obtains product I；X is defined as described above.
Compound of Formula I of the present invention has ROCK inhibitory action, can be used to prepare as active ingredient such as sexual function
The medicine of obstacle, diseases associated with inflammation, ophthalmology disease and respiratory disease etc..The work of compound of Formula I of the present invention
Property be to be verified by vitro suppressing ROCK experiments.
Embodiment
With reference to embodiment, the present invention is further illustrated.It should be noted that following embodiments are only for
Illustrate, and be not intended to limit the present invention.General technical staff's training centre according to the present invention in the art is made various
Change should all be within the protection domain required by the application claim.
The synthesis of 1 compound I-1 of embodiment
The synthesis of step 1. compound IV-1
2.07g (10mmol) compound II-1 and 0.57g (10mmol) compound III is dissolved in the THF of 20mL dryings, room
The lower stirring of temperature, adds 2.48g (12mmol) N, N'- dicyclohexyl carbodiimides (DCC) and 0.1g 4- dimethylamino pyridines
(DMAP), after adding, reaction mixture is stirred at room temperature overnight, and TLC tracking finds that reaction is completed.
Reaction mixture is carefully poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, according to
It is secondary to use 5% salt water washing of 1% dilute hydrochloric acid of 100mL and 100mL, anhydrous sodium sulfate drying.Filter and remove drier, filtrate is being revolved
Turn to be evaporated on evaporimeter, residue is purified using silica gel column chromatography, obtains compound IV-I, 2.29g (yield 93%).ESI-
MS, m/z=247 ([M+H]+)。
The synthesis of step 2. compound VI-1
1.58g (10mmol) compound V-1 and 3.76g (20mmol) B (i-PrO)3It is dissolved in 14mL dry toluenes and 7mL
In THF, stirring, is cooled to -30 DEG C, 6.25mL (10mmol) 1.6M n- is then slowly added dropwise with syringe under nitrogen protection
The hexane solution of BuLi.After being added dropwise, compound of reaction stir at such a temperature 3 it is small when, be then stirred for 3 at room temperature
Hour, TLC tracking finds that reaction is completed.
1mL concentrated hydrochloric acids are slowly added into reaction mixture, when stirring 1 is small at room temperature, then pour into 200mL frozen water
In, with saturation NaHCO3Solution adjusts pH=8, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, with 5% salt of 100mL
Water washing, anhydrous sodium sulfate drying.Filter and remove drier, filtrate is evaporated on a rotary evaporator, and residue uses silicagel column
Chromatographic purifying, obtains compound VI-I, 1.00g (yield 81%).ESI-MS, m/z=124 ([M+H]+)。
The synthesis of step 3. compound VII-1
1.23g (5mmol) compound IV-1,0.61g (5mmol) compound VI-1,0.18g (0.25mmol) Pd (dppf)
Cl2It is added to 1.59g (15mmol) sodium carbonate in 21mL Isosorbide-5-Nitraes-dioxane and 7mL water, reaction mixture is in nitrogen atmosphere
In be stirred overnight at 80 DEG C, TLC tracking finds that reaction is completed.
Reaction mixture is poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, uses
5% salt water washings of 100mL, anhydrous sodium sulfate drying.Filter and remove drier, filtrate is evaporated on a rotary evaporator, residue
Purified using silica gel column chromatography, obtain compound VII-I, 1.06g (yield 87%).ESI-MS, m/z=245 ([M+H]+)。
The synthesis of step 4. compound I-1
0.73g (3mmol) compounds VII-1 is dissolved in 7mL THF and 3mL water, is stirred at room temperature, adds 0.70g
(6mmol) NMMO and 1.2mL (0.3mmol) 0.25M OsO4Solution made of 75% tertiary butanol aqueous solution is dissolved in, after adding,
Compound of reaction is stirred at room temperature overnight, and TLC tracking finds that reaction is completed.
Reaction mixture is poured into 200mL frozen water, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction phase, uses successively
100mL 5%Na2S2O35% salt water washing of aqueous solution and 100mL, anhydrous sodium sulfate drying.Filter and remove drier, filtrate exists
It is evaporated on Rotary Evaporators, residue is purified using silica gel column chromatography, obtains compound I-I, 0.72g (yield 86%).ESI-
MS, m/z=279 ([M+H]+), white solid.
The synthesis of 2 compound I-2 of embodiment
The synthesis of step 1. compound IV-2
2.25g (10mmol) compound II-2 and 0.57g (10mmol) compound III is dissolved in the THF of 20mL dryings, room
The lower stirring of temperature, adds 2.48g (12mmol) N, N'- dicyclohexyl carbodiimides (DCC) and 0.1g 4- dimethylamino pyridines
(DMAP), after adding, reaction mixture is stirred at room temperature overnight, and TLC tracking finds that reaction is completed.Reaction mixture carefully inclines
Pour into 200mL frozen water, stir, with 50mL × 3CH2Cl2Extraction, merges extraction phase, successively with 1% dilute hydrochloric acid of 100mL and
5% salt water washings of 100mL, anhydrous sodium sulfate drying.Filter and remove drier, filtrate is evaporated on a rotary evaporator, residue
Purified using silica gel column chromatography, obtain compound IV-2.ESI-MS, m/z=265 ([M+H]+)。
The synthesis of step 2. compound VI-2
1.86g (10mmol) compound V-2 and 3.76g (20mmol) B (i-PrO)3It is dissolved in 14mL dry toluenes and 7mL
In THF, stirring, is cooled to -30 DEG C, 6.25mL (10mmol) 1.6M n- is then slowly added dropwise with syringe under nitrogen protection
The hexane solution of BuLi.After being added dropwise, compound of reaction stir at such a temperature 3 it is small when, be then stirred for 3 at room temperature
Hour, TLC tracking finds that reaction is completed.1mL concentrated hydrochloric acids are slowly added into reaction mixture, when stirring 1 is small at room temperature, then
Pour into 200mL frozen water, with saturation NaHCO3Solution adjusts pH=8, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction
Phase, with 5% salt water washings of 100mL, anhydrous sodium sulfate drying.Filtering and remove drier, filtrate is evaporated on a rotary evaporator,
Residue is purified using silica gel column chromatography, obtains compound VI-2.ESI-MS, m/z=152 ([M+H]+)。
The synthesis of step 3. compound VII-2
1.32g (5mmol) compound IV-2,0.76g (5mmol) compound VI-2,0.18g (0.25mmol) Pd (dppf)
Cl2It is added to 1.59g (15mmol) sodium carbonate in 21mL Isosorbide-5-Nitraes-dioxane and 7mL water, reaction mixture is in nitrogen atmosphere
In be stirred overnight at 80 DEG C, TLC tracking finds that reaction is completed.Reaction mixture is poured into 200mL frozen water, and stirring, uses 50mL
×3CH2Cl2Extraction, merges extraction phase, with 5% salt water washings of 100mL, anhydrous sodium sulfate drying.Filter and remove drier, filter
Liquid is evaporated on a rotary evaporator, and residue is purified using silica gel column chromatography, obtains compound VII-2.ESI-MS, m/z=291
([M+H]+)。
The synthesis of step 4. compound I-2
0.97g (3mmol) compounds VII-2 is dissolved in 7mL THF and 3mL water, is stirred at room temperature, adds 0.70g
(6mmol) NMMO and 1.2mL (0.3mmol) 0.25M OsO4Solution made of 75% tertiary butanol aqueous solution is dissolved in, after adding,
Compound of reaction is stirred at room temperature overnight, and TLC tracking finds that reaction is completed.Reaction mixture is poured into 200mL frozen water, is stirred
Mix, with 50mL × 3CH2Cl2Extraction, merges extraction phase, successively with 100mL 5%Na2S2O3Aqueous solution and the washing of 5% salt of 100mL
Wash, anhydrous sodium sulfate drying.Filter and remove drier, filtrate is evaporated on a rotary evaporator, and residue uses silica gel column chromatography
Purifying, obtains compound I-2.ESI-MS, m/z=325 ([M+H]+), white powder.
The synthesis of 3 compound I-3 of embodiment
The synthesis of step 1. compound IV-3
2.41g (10mmol) compound II-3 and 0.57g (10mmol) compound III is dissolved in the THF of 20mL dryings, room
The lower stirring of temperature, adds 2.48g (12mmol) N, N'- dicyclohexyl carbodiimides (DCC) and 0.1g 4- dimethylamino pyridines
(DMAP), after adding, reaction mixture is stirred at room temperature overnight, and TLC tracking finds that reaction is completed.Reaction mixture carefully inclines
Pour into 200mL frozen water, stir, with 50mL × 3CH2Cl2Extraction, merges extraction phase, successively with 1% dilute hydrochloric acid of 100mL and
5% salt water washings of 100mL, anhydrous sodium sulfate drying.Filter and remove drier, filtrate is evaporated on a rotary evaporator, residue
Purified using silica gel column chromatography, obtain compound IV-3.ESI-MS, m/z=282 ([M+H]+)。
The synthesis of step 2. compound VI-2
1.86g (10mmol) compound V-2 and 3.76g (20mmol) B (i-PrO)3It is dissolved in 14mL dry toluenes and 7mL
In THF, stirring, is cooled to -30 DEG C, 6.25mL (10mmol) 1.6M n- is then slowly added dropwise with syringe under nitrogen protection
The hexane solution of BuLi.After being added dropwise, compound of reaction stir at such a temperature 3 it is small when, be then stirred for 3 at room temperature
Hour, TLC tracking finds that reaction is completed.1mL concentrated hydrochloric acids are slowly added into reaction mixture, when stirring 1 is small at room temperature, then
Pour into 200mL frozen water, with saturation NaHCO3Solution adjusts pH=8, stirring, with 50mL × 3CH2Cl2Extraction, merges extraction
Phase, with 5% salt water washings of 100mL, anhydrous sodium sulfate drying.Filtering and remove drier, filtrate is evaporated on a rotary evaporator,
Residue is purified using silica gel column chromatography, obtains compound VI-2.ESI-MS, m/z=152 ([M+H]+)。
The synthesis of step 3. compound VII-3
1.41g (5mmol) compound IV-3,0.76g (5mmol) compound VI-2,0.18g (0.25mmol) Pd (dppf)
Cl2It is added to 1.59g (15mmol) sodium carbonate in 21mL Isosorbide-5-Nitraes-dioxane and 7mL water, reaction mixture is in nitrogen atmosphere
In be stirred overnight at 80 DEG C, TLC tracking finds that reaction is completed.Reaction mixture is poured into 200mL frozen water, and stirring, uses 50mL
×3CH2Cl2Extraction, merges extraction phase, with 5% salt water washings of 100mL, anhydrous sodium sulfate drying.Filter and remove drier, filter
Liquid is evaporated on a rotary evaporator, and residue is purified using silica gel column chromatography, obtains compound VII-3.ESI-MS, m/z=308
([M+H]+)。
The synthesis of step 4. compound I-3
0.92g (3mmol) compounds VII-3 is dissolved in 7mL THF and 3mL water, is stirred at room temperature, adds 0.70g
(6mmol) NMMO and 1.2mL (0.3mmol) 0.25M OsO4Solution made of 75% tertiary butanol aqueous solution is dissolved in, after adding,
Compound of reaction is stirred at room temperature overnight, and TLC tracking finds that reaction is completed.Reaction mixture is poured into 200mL frozen water, is stirred
Mix, with 50mL × 3CH2Cl2Extraction, merges extraction phase, successively with 100mL 5%Na2S2O3Aqueous solution and the washing of 5% salt of 100mL
Wash, anhydrous sodium sulfate drying.Filter and remove drier, filtrate is evaporated on a rotary evaporator, and residue uses silica gel column chromatography
Purifying, obtains compound I-3.ESI-MS, m/z=342 ([M+H]+), white solid.
4 Compound ira vitro of embodiment suppresses ROCK analyses
Using the ROCK IMAP kits (product identification R8093) from Molecular Devices companies markets, and
Inhibition test is performed with fluorescence polarization (FP) method essentially according to the scheme that manufacturer provides.S6 ribosomal proteins source property bottom used
Thing is (Fl)-AKRRRLSSLRA, also from Molecular Devices companies (product identification R7184).ROCKα/
The enzymatic mixture of ROCKII comes from Upstate Biotechnology companies (product identification 14-451).In brief, Suo Youhua
Compound is placed into 384 orifice plates and is screened to measure enzyme suppression, concentration used between 100 μM between 0.1nM, using in proper order gradually
Into 3 times of dilution methods.Y-27632 is used as reference (0.4 μM) (by Tocris companies markets) to perform experiment.Will be
The 1 μ L compound solutions (each concentration) tested in DMSO be put into 10mM Tris-HCl, 10mM MgCl2,0.1%BSA,
In 0.05%NaN3, the 2 μ L enzyme solutions that pH value is 7.2.The ultimate density of enzyme is 2.6nM.After incubating 30 minutes at room temperature, add
The ATP for adding 2 μ L is in 10mM Tris-HCl, 10mM MgCl2,0.1%BSA, 0.05%NaN3, pH value with protein substrate
Mixture in 7.2 solution.Final concentration of 10 μM of ATP, and the ultimate density of protein substrate is then 0.2 μM.At room temperature
Incubate after sixty minutes, (IMAP combination buffers A (1x) and IMAP binding reagents (come from the IMAP binding solns of 12 μ L of addition
ROCK IMAP kits) mixture).Mixture (the cumulative volume so obtained is incubated at room temperature：17 μ L) 60 minutes, make
Fluorescence polarization degree, wherein FP filters are measured with automatic flat-plate reader (Perkin Elmer, Envision 2100-0010HTS types)
Ripple device is given out light optical filter using FITC FP480 exciter filters and FITC FP P-pol535 and FITC FP S-pol535
(Perkin-Elmer).Result is fitted to a curve using XL-Fit algorithms, is then calculated again with XL-Fit algorithms every
The IC of a matched curve50Value.
As a result see the table below.
| Compound | IC50(nM) |
| Compound I-1 | 334.9 |
| Compound I-2 | 46.2 |
| Compound I-3 | 98.6 |
The compound that can be seen that the present invention from upper table result has very strong inhibitory action to ROCK, can be used as system
Standby treatment inflammation in respiratory system disease medicament.
Claims (3)
1. the compound with logical formula (I) structure,
Wherein, R is selected from F, Cl substituent.
2. synthesize the method for compound described in claim 1：
Thiophene carboxylic acid's compound II is condensed with allylamine III in the presence of DCC, generation thiophene-carboxamides IV；Pyridine bromide V is in boric acid
Handled in the presence of three isopropyl esters using n-BuLi, obtain compound VI；Compound IV and compound VI reacts bar in Suzuki
Reacted under part, coupling obtains compound VII；Compound VII uses OsO4With N-methylmorpholine N- oxides (NMMO) processing, obtain
To product I；The definition of X such as claim 1 is any described.
3. claim 1 logical formula (I) compound as defined in any one is preparing answering for treatment medicament for treating respiratory system object space face
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711495907.XA CN107936003A (en) | 2017-12-31 | 2017-12-31 | A kind of compound containing pyridine and thiophene-structure, preparation method and its usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711495907.XA CN107936003A (en) | 2017-12-31 | 2017-12-31 | A kind of compound containing pyridine and thiophene-structure, preparation method and its usage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107936003A true CN107936003A (en) | 2018-04-20 |
Family
ID=61938257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711495907.XA Pending CN107936003A (en) | 2017-12-31 | 2017-12-31 | A kind of compound containing pyridine and thiophene-structure, preparation method and its usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107936003A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008049919A2 (en) * | 2006-10-26 | 2008-05-02 | Devgen N.V. | Rho kinase inhibitors |
-
2017
- 2017-12-31 CN CN201711495907.XA patent/CN107936003A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008049919A2 (en) * | 2006-10-26 | 2008-05-02 | Devgen N.V. | Rho kinase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| 孟令芝 等: "《有机波谱分析》", 31 July 2016 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107973777A (en) | One kind contains methyl naphthalene and propane diols thiophene-carboxamides class ROCK inhibitor and application thereof | |
| CN108191821A (en) | A kind of ROCK inhibitor and purposes containing methyl naphthalene and cyano-thiophene amide class formation | |
| CN108129453A (en) | A kind of ROCK inhibitor containing methyl naphthalene and propylene glycol thiophene-carboxamides class formation | |
| CN108047193A (en) | Alcoxyl thiophene-carboxamides class ROCK inhibitor, preparation method and its usage | |
| CN108047197A (en) | Nitrothiophene amide ROCK inhibitor, preparation method and its usage | |
| CN108129448A (en) | Thiophene-carboxamides class ROCK inhibitor, preparation method and its usage | |
| CN108558823A (en) | A kind of cyano-thiophene amide ROCK inhibitor, preparation method and its usage | |
| JP6152921B2 (en) | Anti-angiogenic compounds, intermediates and uses thereof | |
| WO2001015717A1 (en) | Brain cell or nerve cell protecting agents comprising ginseng | |
| CN107936003A (en) | A kind of compound containing pyridine and thiophene-structure, preparation method and its usage | |
| CN108033953A (en) | A kind of compound containing pyridine and alcoxyl thiophene-structure, preparation method and its usage | |
| CN108033954A (en) | A kind of pyridine structure contained compound, preparation method and its usage | |
| CN107903250A (en) | A kind of compound containing pyridine and nitrothiophene structure, preparation method and its usage | |
| CN107935987A (en) | ROCK inhibitor, preparation method and its usage containing methyl naphthalene and thiophene-carboxamides structure | |
| CN107915717A (en) | One kind contains isopropyl naphthalene and propane diols thiophene-carboxamides class compound and application thereof | |
| CN108047214A (en) | One kind contains pyridine and nitrothiophene structural compounds and application thereof | |
| CN108047215A (en) | Pyridine structure contained compound, preparation method and its usage | |
| CN107973776A (en) | A kind of thiophene-carboxamides type of structured compound and application thereof | |
| CN107935986A (en) | Isopropylamine and halogenated thiophene amide-type structural compounds, preparation method and the usage | |
| WO2004110449A1 (en) | Aporphine and oxoaporphine and the medical use thereof | |
| CN108047192A (en) | First thiophene-carboxamides class formation compound, preparation method and the usage | |
| CN108047195A (en) | A kind of amides compound of cyano-thiophene containing propylene glycol and application thereof | |
| CN108129452A (en) | One kind contains isopropyl naphthalene and propylene glycol nitrothiophene amides compound and application thereof | |
| CN108084149A (en) | Containing isopropyl naphthalene and propylene glycol thiophene-carboxamides class compound, preparation method and its usage | |
| CN108047194A (en) | Containing methyl naphthalene and propylene glycol thiophene-carboxamides class compound, preparation method and its usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180420 |